# A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)

> **NCT06515002** · PHASE1,PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 5 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **GENETIC:** BI 3720931
- **DRUG:** Placebo
- **DEVICE:** Inhaler

## Key facts

- **NCT ID:** NCT06515002
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-11-04
- **Primary completion:** 2026-02-03
- **Final completion:** 2026-02-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06515002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06515002, "A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06515002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*